Sarcopenia is frequently seen in patients with liver cirrhosis and an independent risk factor for poor prognosis [
1-
5]. Sarcopenia is an important therapeutic target. However, its pathogenesis remains unclear, and a therapeutic strategy has not been established in patients with liver cirrhosis [
1,
5]. A recent study by Han et al. [
6] investigated the association of liver cirrhosis-related systemic inflammation with sarcopenia in a rat model of liver cirrhosis. They found that tumor necrosis factor-α (TNF-α) was associated with the expression of intestinal tight junction proteins, muscular myostatin, and sarcopenia in a rat model of liver cirrhosis. Furthermore, they reported that treatment with rifaximin caused muscle hypertrophy with a reduction in both serum TNF-α levels and expression of muscular myostatin in a rat model of liver cirrhosis. Thus, they revealed that 1) TNF-α is involved in the pathogenesis of sarcopenia, and 2) rifaximin is a possible therapeutic strategy for liver cirrhosis-related sarcopenia through the downregulation of TNF-α.
Aging and physical inactivity are the main mechanisms underlying the development of sarcopenia [
1]. Besides these factors, various liver-related metabolic dysfunctions are involved in the pathogenesis of sarcopenia in patients with liver cirrhosis [
1,
5,
7]. The metabolic dysfunctions are depletion of branched-chain amino acids, carnitine, vitamin D, testosterone, and hyperammonemia [
1,
5,
7]. In patients with liver cirrhosis, chronic inflammation is associated with development of various complications including ascites. However, information is limited on the association between inflammatory cytokines and sarcopenia. Han et al. [
6] found a significant negative correlation of serum TNF-α level with muscle weight and myofiber diameter in a rat model of liver cirrhosis. Furthermore, they found that serum TNF-α levels were significantly higher in patients with sarcopenia than in those without sarcopenia [
6]. Shiraki et al. [
8] previously reported that, in patients with liver cirrhosis, elevated serum TNF-α levels were associated with malnutrition. In addition, TNF-α has been reported to promote myosin heavy-chain degradation and apoptosis of muscle fibers, leading to muscle atrophy [
9,
10]. These findings suggest that upregulation of TNF-α is important in the pathogenesis of sarcopenia in patients with liver cirrhosis.
In the liver, TNF-α is mainly released from Kupffer cells and hepatic stellate cells by stimulation of intestinal bacteria and their products, including lipopolysaccharide [
11]. Therefore, increased intestinal permeability seems to be an upstream event for the upregulation of serum TNF-α levels in patients with liver cirrhosis. In fact, a variety of basic and clinical studies have implicated that gut dysbiosis affects the intestinal epithelial barrier and leads to translocation of gut contents to the liver and beyond [
12,
13]. Intestinal permeability is regulated by intercellular adhesion complexes called tight junctions [
14]. Han et al. [
6] demonstrated that expression of tight junction proteins such as occludin and zonula occludens-1 (ZO-1) in the intestine were inversely correlated with serum TNF-α levels in a rat model of liver cirrhosis. These findings are in line with results of previous studies. Intestinal expression of claudin-1 and occludin, tight junction proteins, has been reported to be associated with endotoxin levels in a rat model of liver cirrhosis [
15]. Intestinal expression of claudin-1 has also been reported to be reduced and inversely correlated with endotoxin concentrations in patients with liver cirrhosis [
16]. Furthermore, Han et al. [
6] first demonstrated that intestinal expression levels of occludin and ZO-1 were positively correlated with muscle weight and myofiber diameter. Taken together, disruption of the intestinal tight junction may be responsible for the influx of lipopolysaccharide into the liver. Lipopolysaccharide stimulates Kupffer cells and hepatic stellate cells, leading to releasing TNF-α. Upregulated TNF-α causes sarcopenia in patients with liver cirrhosis (
Fig. 1).
Hyperammonemia is also a risk factor for sarcopenia in patients with liver cirrhosis [
17]. Rifaximin suppresses ammonia-producing colonic bacteria and improves hyperammonemia [
18]. In addition, rifaximin alters the gut microbiome composition (
Lactobacillus,
Streptococcus,
Veillonella), which contributes to reducing hyperammonemia and endotoxemia in cirrhosis [
18]. Furthermore, rifaximin has been reported to increase circulating saturated and unsaturated fatty acids and to modulate the metabolism of the host [
19,
20]. Ammonia-lowering treatment, including rifaximin, has been reported to reverse sarcopenia in a rat model of hyperammonemia by restoring skeletal muscle proteostasis [
21]. Han et al. [
6] demonstrated that treatment with rifaximin increased muscle mass and myofiber diameter in a rat model of cirrhosis. However, no reduction in blood ammonia levels was observed in rifaximin-treated rats compared to control rats. In contrast, rifaximin significantly reduced serum TNF-α levels and muscular expression of myostatin. Rifaximin has been reported to upregulate ZO-1 and reduce portal endotoxin levels in a rat model of liver cirrhosis [
22]. Rifaximin has also been reported to reduce endotoxin activity and improve intestinal permeability, as evaluated by serum soluble CD163 and mannose receptors in patients with liver cirrhosis [
23]. Accordingly, rifaximin may tighten the intestinal barrier and suppress serum TNF-α levels, leading to an improvement in sarcopenia with downregulation of myostatin expression.
The study by Han et al. showed that TNF-α is involved in the pathogenesis of sarcopenia in a rat model of liver cirrhosis. They also showed that rifaximin reduced serum TNF-α levels and improved sarcopenia in a rat model of liver cirrhosis. However, this study had some limitations. First, the pathogenesis of an increase in intestinal permeability remains unclear. Rifaximin is a non-systemic antibiotic that has been reported to alter the gut microbiota components in patients with liver cirrhosis [
18]. Gut microbiota components are associated with various metabolites that regulate intestinal permeability and inflammatory cytokines [
11,
24]. Therefore, it is important to evaluate the impact of alterations in gut microbiota components and their metabolites on intestinal permeability. Second, it remains unclear whether rifaximin has an additive effect on nutritional and exercise therapies for sarcopenia. Third, it also remains unclear whether improvement of sarcopenia suppresses disease progression, development of life-threatening complications, and mortality in patients with liver cirrhosis. Further studies should focus on the effects of the combination of nutritional/exercise therapies and rifaximin treatment on long-term outcomes in patients with liver cirrhosis.
Alterations in intestinal permeability and inflammatory cytokines are crucial in the pathogenesis of sarcopenia in patients with liver cirrhosis. Further elucidation of the gut-liver-muscle axis may serve as a therapeutic strategy for sarcopenia.
ACKNOWLEDGMENTS
This work was supported by Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (C) JP20K08395 and by the Research Program on Hepatitis from Japan Agency for Medical Research and Development, AMED under 21fk0210094.
FOOTNOTES
-
Authors’ contributions
All authors were responsible for the interpretation of data, the drafting, and the critical revision of the manuscript for important intellectual content.
-
Conflicts of Interest
Takumi Kawaguchi received lecture fees from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, and Otsuka Pharmaceutical Co., Ltd. The other author has no conflicts of interest.
Figure 1.A proposed gut-liver-muscle axis of liver cirrhosis-related sarcopenia. Disruption of the intestinal tight junction causes an influx of lipopolysaccharide into the liver. Lipopolysaccharide stimulates Kupffer cells and hepatic stellate cells and releases TNF-α. Then, TNF-α causes sarcopenia. LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-α.
Abbreviations
REFERENCES
- 1. Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol 2021;75 Suppl 1:S147-S162.
- 2. Han J, Kim W. Prognostic implications of trunk muscle mass in liver cirrhosis. Clin Mol Hepatol 2018;24:297-298.
- 3. Oh S, Lee J. Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma. Clin Mol Hepatol 2020;26:476-479.
- 4. Choi K, Jang HY, Ahn JM, Hwang SH, Chung JW, Choi YS, et al. The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma. Clin Mol Hepatol 2020;26:492-505.
- 5. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-749.
- 6. Han JW, Kim DI, Nam HC, Chang UI, Yang JM, Song DS, et al. Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis. Clin Mol Hepatol 2022;28:219-231.
- 7. Koya S, Kawaguchi T, Hashida R, Goto E, Matsuse H, Saito H, et al. Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease. Hepatol Res 2017;47:E22-E34.
- 8. Shiraki M, Terakura Y, Iwasa J, Shimizu M, Miwa Y, Murakami N, et al. Elevated serum tumor necrosis factor-alpha and soluble tumor necrosis factor receptors correlate with aberrant energy metabolism in liver cirrhosis. Nutrition 2010;26:269-275.
- 9. Phillips T, Leeuwenburgh C. Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction. FASEB J 2005;19:668-670.
- 10. Li J, Yi X, Yao Z, Chakkalakal JV, Xing L, Boyce BF. TNF receptor-associated factor 6 mediates TNFα-induced skeletal muscle atrophy in mice during aging. J Bone Miner Res 2020;35:1535-1548.
- 11. Nishimura N, Kaji K, Kitagawa K, Sawada Y, Furukawa M, Ozutsumi T, et al. Intestinal permeability is a mechanical rheostat in the pathogenesis of liver cirrhosis. Int J Mol Sci 2021;22:6921.
- 12. Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology 2020;159:849-863.
- 13. Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, et al. The gut barrier, intestinal microbiota, and liver disease: molecular mechanisms and strategies to manage. Int J Mol Sci 2020;21:8351.
- 14. Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, et al. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology 2000;31:1285-1295.
- 15. Zhao TY, Su LP, Ma CY, Zhai XH, Duan ZJ, Zhu Y, et al. IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats. BMC Gastroenterol 2015;15:77.
- 16. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE, et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest 2012;42:439-446.
- 17. Jindal A, Jagdish RK. Sarcopenia: ammonia metabolism and hepatic encephalopathy. Clin Mol Hepatol 2019;25:270-279.
- 18. Kawaguchi T, Suzuki F, Imamura M, Murashima N, Yanase M, Mine T, et al. Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: an exploratory data analysis of phase II/III clinical trials. Hepatol Res 2019;49:404-418.
- 19. Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013;8:e60042.
- 20. Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021;75 Suppl 1:S67-S81.
- 21. Kumar A, Davuluri G, Silva RNE, Engelen MPKJ, Ten Have GAM, Prayson R, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology 2017;65:2045-2058.
- 22. Fujinaga Y, Kawaratani H, Kaya D, Tsuji Y, Ozutsumi T, Furukawa M, et al. Effective combination therapy of angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis. Int J Mol Sci 2020;21:5589.
- 23. Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, et al. Rifaximin alleviates endotoxemia with decreased serum levels of soluble CD163 and mannose receptor and partial modification of gut microbiota in cirrhotic patients. Antibiotics (Basel) 2020;9:145.
- 24. Gao J, Guo X, Wei W, Li R, Hu K, Liu X, et al. The association of fried meat consumption with the gut microbiota and fecal metabolites and its impact on glucose homoeostasis, intestinal endotoxin levels, and systemic inflammation: a randomized controlled-feeding trial. Diabetes Care 2021;44:1970-1979.
Citations
Citations to this article as recorded by
- Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
Cells.2025; 14(6): 428. CrossRef - The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi
Internal Medicine.2025;[Epub] CrossRef - Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c
Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef - Interaction between sarcopenia and nonalcoholic fatty liver disease
Sae Kyung Joo, Won Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S68. CrossRef - An ultrasensitive photoelectrochemical assay for tumor necrosis factor-alpha based on hollow CdS cubes as a signal generator and NiCo2O4-Au as a signal extinguisher
Yamin Fu, Baohuan Fan, Shenzhen Chang, Dongyu Guo, Fuxiang Wang, Qinhe Pan
The Analyst.2023; 148(19): 4746. CrossRef - Role of increased intestinal permeability in the development and progression of liver diseases
S. N. Mekhtiyev, O. A. Mekhtiyeva, O. M. Berko, A. M. Kolodkin
Experimental and Clinical Gastroenterology.2023; (12): 130. CrossRef
